RLAY
4:05 PM
Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates
Selected z ovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine - sensitive patients expected to initiate in early 2027, subject to regulatory feedback Presented initial positive clinical data from Phase 1/2 ReInspire trial in vascular
Presentation / Abstract • Phase 1/2relaytx.com